2026-2034年人工智慧（AI）驱动药物发现全球市场规模、份额、趋势和成长分析报告

预计人工智慧（AI）在製药开发领域的市场规模将从2025年的33.6亿美元成长到2034年的356.8亿美元，2026年至2034年的复合年增长率为30.04%。

随着製药公司寻求缩短研发时间和降低研发成本，人工智慧在药物发现领域的市场正经历显着成长。机器学习、深度学习和自然语言处理等人工智慧技术正被用于识别药物标靶、预测分子行为以及优化临床候选化合物的选择。生技Start-Ups与大型製药企业之间合作的加强，正在加速人工智慧在早期研发阶段的应用。

关键驱动因素包括药物研发成本不断上涨、提高成功率的需求以及取得大量生物医学数据。人工智慧平台能够增强标靶检验、化合物筛检和毒性预测，从而缩短药物发现週期。运算能力的进步和基于云端的分析技术进一步提升了扩充性。创业投资对人工智慧主导生物技术公司的投入正在推动创新并拓展竞争格局。

未来，人工智慧有望成为药物研发全过程不可或缺的一部分，包括临床试验设计和真实世界数据分析。与基因组学、蛋白质组学和患者数据的整合将实现更精准的治疗方法。监管机构对人工智慧产生的洞见和数据透明度的认可预计将对长期发展产生影响。随着演算法的成熟和检验准确性的提高，人工智慧主导的开发平臺有望显着变革药物创新。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球人工智慧（AI）药物研发市场：按应用领域划分

• 市场分析、洞察与预测
• 药物优化和再利用
• 临床前试验
• 其他的

第五章：全球药物研发市场－人工智慧（AI）应用：依治疗领域划分

• 市场分析、洞察与预测
• 肿瘤学
• 神经退化性疾病
• 心血管疾病
• 代谢性疾病
• 感染疾病
• 其他的

第六章：全球人工智慧（AI）药物发现市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第七章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第八章：公司简介

• 主要公司的市占率分析
• 公司简介
  • IBM Corporation
  • Exscientia Plc
  • Insilico Medicine Inc
  • Aitia（Formerly GNS Healthcare）
  • Google DeepMind
  • BenevolentAI
  • BioSymetrics Inc
  • Berg Health（Acquired By BPGbio）
  • Atomwise Inc
  • Insitro
  • Cyclica（Now Part Of Recursion Pharmaceuticals）

The Artificial Intelligence (AI) in Drug Discovery Market size is expected to reach USD 35.68 Billion in 2034 from USD 3.36 Billion (2025) growing at a CAGR of 30.04% during 2026-2034.

The AI in drug discovery market has witnessed significant growth as pharmaceutical companies seek to reduce R&D timelines and costs. AI technologies-such as machine learning, deep learning, and natural language processing-are used to identify drug targets, predict molecular behavior, and optimize clinical candidate selection. Growing collaboration between biotech startups and large pharmaceutical firms has accelerated AI adoption in early-stage research.

Primary drivers include rising drug development costs, the need for higher success rates, and access to vast biomedical datasets. AI platforms enhance target validation, compound screening, and toxicity prediction, shortening discovery cycles. Advances in computational power and cloud-based analytics further support scalability. Venture capital investment in AI-driven biotech firms has fueled innovation and expanded the competitive landscape.

Looking ahead, AI is expected to become integral across the drug development continuum, including clinical trial design and real-world evidence analysis. Integration with genomics, proteomics, and patient data will enable more precise therapies. Regulatory acceptance of AI-generated insights and data transparency will influence long-term growth. As algorithms mature and validation improves, AI-driven pipelines may significantly reshape pharmaceutical innovation.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Application

• Drug Optimization and Repurposing
• Preclinical Testing
• Others

By Therapeutic Area

• Oncology
• Neurodegenerative Diseases
• Cardiovascular Disease
• Metabolic Diseases
• Infectious Disease
• Others

COMPANIES PROFILED

• IBM Corporation, Exscientia plc, Insilico Medicine Inc, Aitia formerly GNS Healthcare, Google DeepMind, BenevolentAI, BioSymetrics Inc, Berg Health acquired by BPGbio, Atomwise Inc, insitro, Cyclica now part of Recursion Pharmaceuticals
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY APPLICATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Application
• 4.2. Drug Optimization and Repurposing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Preclinical Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Therapeutic Area
• 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Neurodegenerative Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Cardiovascular Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Metabolic Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Infectious Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Application
  • 6.2.2 By Therapeutic Area
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Application
  • 6.3.2 By Therapeutic Area
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Application
  • 6.4.2 By Therapeutic Area
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Application
  • 6.5.2 By Therapeutic Area
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Application
  • 6.6.2 By Therapeutic Area
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 IBM Corporation
  • 8.2.2 Exscientia Plc
  • 8.2.3 Insilico Medicine Inc
  • 8.2.4 Aitia (Formerly GNS Healthcare)
  • 8.2.5 Google DeepMind
  • 8.2.6 BenevolentAI
  • 8.2.7 BioSymetrics Inc
  • 8.2.8 Berg Health (Acquired By BPGbio)
  • 8.2.9 Atomwise Inc
  • 8.2.10 Insitro
  • 8.2.11 Cyclica (Now Part Of Recursion Pharmaceuticals)